British-Swedish multinational pharmaceutical and biotechnology company with an India-listed arm in Bengaluru.
astrazeneca.comLegal Name
AstraZeneca plc
Founded
1999 (merger of Astra AB and Zeneca Group)
Industry
Pharmaceutical and biotechnology
Headquarters
Cambridge, England, United Kingdom
Employees
89,900 (2025)Revenue (FY25)
US$58.74 billion
Market Cap
US$259.2 billion (July 2026)
Listed on
LSE, Nasdaq and Nasdaq Stockholm (AZN)
CEO
Pascal Soriot
Website
astrazeneca.comAstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company headquartered in Cambridge, England. It was formed in 1999 through the merger of Sweden's Astra AB and the UK's Zeneca Group, and its shares trade on the London Stock Exchange, Nasdaq in the US, and Nasdaq Stockholm under the ticker AZN. The company reported revenue of US$58.74 billion for 2025 and employed about 89,900 people that year.
The business is run by CEO Pascal Soriot, who has led the company since 2012, with Aradhana Sarin as Chief Financial Officer and Michel Demare serving as Non-Executive Chair of the Board. AstraZeneca develops and markets prescription medicines across oncology, cardiovascular, renal and metabolic disease, respiratory, and rare diseases, and it carries a market capitalisation of roughly US$259 billion as of July 2026.
In India the company operates through AstraZeneca Pharma India Limited (CIN L24231KA1979PLC003563), a listed subsidiary about 75% owned by the AstraZeneca group and registered at Manyata Embassy Business Park in Bengaluru. The India arm is led by Country President and Managing Director Sanjeev Panchal, is listed on the BSE (506820) and NSE (ASTRAZEN), and reported net revenue of ₹1,713 crore for FY2024-25.
Chief Executive Officer, AstraZeneca plc
Non-Executive Chair of the Board
Chief Financial Officer, AstraZeneca plc
Country President and Managing Director, AstraZeneca India
Interview experience
Favorable
Interview difficulty
Medium
Interview process length
About a week
Practice real questions and get instant feedback before the call.
Q: Sell me this product using this water cup.
A: This is a role-play test of how you frame value under pressure, so pick a clear benefit of the cup and tie it to a real customer need rather than listing features.
Q: How do you deal with a doctor who won't see sales reps?
A: Show persistence with respect: describe building access through staff relationships, useful clinical information, and flexible timing rather than pushing harder.
Q: Why are you in sales?
A: Connect your motivation to helping customers solve problems and to measurable results, keeping the answer specific to healthcare where you can.
Q: When was a situation where you solved a difficult problem, and how did you handle it?
A: Use the STAR structure: set the Situation and Task, walk through the Actions you personally took, and finish with a measurable Result.
Practice real questions and get instant feedback before the call.
Average annual
₹7,43,334/yr
9 Salaries submitted
Average annual
₹11,66,257/yr
6 Salaries submitted
Average annual
₹13,56,579/yr
6 Salaries submitted
Average annual
₹13,98,340/yr
5 Salaries submitted
Average annual
₹10,92,418/yr
8 Salaries submitted
Average annual
₹15,13,941/yr
3 Salaries submitted
See how your pay compares and find roles that match your target.
Mumbai, Maharashtra, India • Full-time
Bengaluru, Karnataka, India • Full-time
Chennai, Tamil Nadu, India • Full-time
Bengaluru, Karnataka, India • Full-time
Bengaluru, Karnataka, India • Full-time
Chennai, Tamil Nadu, India • Full-time
Tailor your resume to AstraZeneca roles in minutes.
July 16, 2026
AstraZeneca Pharma India gets CDSCO nod for Benralizumab in Hypereosinophilic Syndrome
CDSCO approved import and sale of Benralizumab (Fasenra) 30 mg/mL pre-filled syringe on July 15, 2026 to treat Hypereosinophilic Syndrome in patients aged 12 and older. It follows a May 2026 clearance of the same drug for relapsing or refractory EGPA.
#AstraZeneca #CDSCO #Oncology
View postJune 11, 2026
AstraZeneca India wins CDSCO approval for Enhertu in first-line HER2-positive breast cancer
AstraZeneca Pharma India received CDSCO permission on June 10, 2026 to import Trastuzumab deruxtecan (Enhertu) for first-line treatment of adults with unresectable or metastatic HER2-positive breast cancer, used with pertuzumab.
#AstraZeneca #BreastCancer #Enhertu
View postJune 1, 2026
AstraZeneca India revenue climbs 33% to Rs 22.76 billion in FY26
AstraZeneca Pharma India posted a 33% year-on-year rise in revenue from operations to Rs 22,755.8 million for the year ended March 31, 2026, with profit after exceptional items and tax of Rs 1,875.2 million.
#AstraZeneca #Earnings #IndiaPharma
View postMay 27, 2026
AstraZeneca Pharma India Q4 FY26: strong revenue, margin pressure
Q4 FY26 revenue from operations rose about 20% year-on-year to roughly Rs 578.6 crore, but net profit fell around 23% to about Rs 44.9 crore as operating margins compressed. The stock slipped on the results.
#AstraZeneca #Q4Results #Margins
View postJune 26, 2025
AstraZeneca expands Bengaluru Global Hub with Rs 166 crore, creating 400 jobs
AstraZeneca committed Rs 166 crore to expand its Bengaluru Global Hub, adding 400 jobs and taking the new building's capacity to around 1,300 employees across R&D, global business services, IT and digital health. Combined AZIPL workforce nears 4,000.
#AstraZeneca #Bengaluru #Hiring
View postAstraZeneca is a British-Swedish pharmaceutical and biotechnology company that develops and markets prescription medicines across oncology, cardiovascular, renal and metabolic disease, respiratory, and rare diseases.
